Adamis Pharmaceuticals
2658 Del Mar Heights Road
Suite 555
Del Mar
California
92014
United States
185 articles about Adamis Pharmaceuticals
-
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19Interim DSMB review expected in late September
7/29/2022
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19.
-
Adamis Pharmaceuticals Issues Letter to Stockholders
7/21/2022
Adamis Pharmaceuticals Corporation issued the following letter to stockholders from Chief Executive Officer David J. Marguglio.
-
Adamis Appoints Vickie Reed to Board of Directors
5/26/2022
Adamis Pharmaceuticals Corporation announced the appointment of Vickie Reed as a new director and member of the company’s board of directors.
-
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
5/18/2022
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, today announced a leadership transition plan to support its efforts to unlock long-term growth and value creation opportunities:
-
Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/16/2022
Adamis Pharmaceuticals Corporation, a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, announced financial results for the quarter ending March 31, 2022.
-
Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update
5/9/2022
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, May 16, 2022 at 2 p.m. Pacific Time to discuss its financial and operating results for the first quarter 2022 as well as provide a business update.
-
US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product
3/31/2022
USWM, LLC, and Adamis Pharmaceuticals Corporation, announced the U.S. launch and availability of ZIMHI™ 5 mg/0.5 mL. ZIMHI is a high-dose naloxone injection product FDA-approved for use in the treatment of opioid overdose as emergency therapy in settings where opioids may be present.
-
Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update
3/31/2022
Adamis Pharmaceuticals Corporation, a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, announced financial results for the year ended December 31, 2021.
-
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update
3/24/2022
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced that it will host an investor conference call on Thursday, March 31, 2022 at 2 p.m. Pacific Time to discuss its financial and operating results for the fourth quarter and full year 2021 as well as provide a business update.
-
Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model
3/22/2022
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with high levels of the Omicron variant of the SARS-CoV-2 virus, resulted in significant decrease of inflammation in the lungs of animals treated with Tempol compared to controls.
-
Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect
3/21/2022
Adamis Pharmaceuticals Corporation is voluntarily recalling certain lots of SYMJEPI Injection 0.15 mg and 0.3 mg Pre-Filled Single-Dose Syringes to the consumer level.
-
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19DSMB met to evaluate interim clinical and safety data and clears Phase 2/3 study to continue
3/14/2022
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that on March 11, 2022, the Data Safety Monitoring Board (DSMB) overseeing the Phase 2/3 clinical trial investigating the use of Tempol for the treatment of COVID-19, met to evaluate the clinical and safety data from the first planned interim analysis.
-
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
-
Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board
3/4/2022
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the retirement of Richard C. Williams, effective April 15, 2022.
-
The study, which has yet to be peer-reviewed, found the Pfizer-BioNTech vaccine was only about 12% effective for children ages 5 to 11 years against the Omicron variant.
-
Adamis Pharmaceuticals’ Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations
2/28/2022
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that due to the acceleration of patient enrollment in the double-blind placebo controlled Phase 2/3 trial for Tempol for the treatment of COVID-19.
-
Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 18, 2022
2/18/2022
Adamis Pharmaceuticals Corporation announced that the compensation committee of the board of directors and the company’s independent directors approved the grant of stock options on February 15, 2022, to purchase an aggregate of 130,000 shares of common stock to two non-officer employees who were not previously employees of the company.
-
Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19
2/7/2022
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3 study of Tempol for the treatment of COVID-19.
-
Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19
1/10/2022
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) for Tempol for the treatment and prevention of COVID-19.